Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

NCT00942799 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Genz-644282 (28-day dosing schedule)
DRUG: Genz-644282 (21-day dosing schedule)

Sponsor

Genzyme, a Sanofi Company